Keith B. Glaser

6.6k total citations · 1 hit paper
108 papers, 4.9k citations indexed

About

Keith B. Glaser is a scholar working on Molecular Biology, Oncology and Hematology. According to data from OpenAlex, Keith B. Glaser has authored 108 papers receiving a total of 4.9k indexed citations (citations by other indexed papers that have themselves been cited), including 53 papers in Molecular Biology, 24 papers in Oncology and 16 papers in Hematology. Recurrent topics in Keith B. Glaser's work include Histone Deacetylase Inhibitors Research (17 papers), Protein Degradation and Inhibitors (17 papers) and Acute Myeloid Leukemia Research (11 papers). Keith B. Glaser is often cited by papers focused on Histone Deacetylase Inhibitors Research (17 papers), Protein Degradation and Inhibitors (17 papers) and Acute Myeloid Leukemia Research (11 papers). Keith B. Glaser collaborates with scholars based in United States, United Kingdom and Singapore. Keith B. Glaser's co-authors include Steven K. Davidsen, Robert S. Jacobs, Alejandro M. S. Mayer, Michael J. Staver, Jeffrey F. Waring, Roger G. Ulrich, Joshua D. Stender, Michael L. Curtin, Patrick A. Marcotte and Daniel H. Albert and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Journal of Clinical Investigation.

In The Last Decade

Keith B. Glaser

103 papers receiving 4.7k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

The odyssey of marine pharmaceuticals: a current pipeline perspective

2010 441 citations Alejandro M. S. Mayer, Keith B. Glaser et al. profile →

Peers

Countries citing papers authored by Keith B. Glaser

Since Specialization

Citations

This map shows the geographic impact of Keith B. Glaser's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Keith B. Glaser with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Keith B. Glaser more than expected).

Fields of papers citing papers by Keith B. Glaser

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Keith B. Glaser. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Keith B. Glaser. The network helps show where Keith B. Glaser may publish in the future.

Co-authorship network of co-authors of Keith B. Glaser

This figure shows the co-authorship network connecting the top 25 collaborators of Keith B. Glaser. A scholar is included among the top collaborators of Keith B. Glaser based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Keith B. Glaser. Keith B. Glaser is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Marine-Derived Pharmaceuticals in Clinical Trials in 2022 2023 ·Journal of Pharmacology and Experimental Therapeutics ·Alejandro M. S. Mayer, Marsha L. Pierce, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), David Newman, Keith B. Glaser	2
2	Identification of novel resistance mechanisms to NAMPT inhibition via the de novo NAD+ biosynthesis pathway and NAMPT mutation 2017 ·Biochemical and Biophysical Research Communications ·Jun Guo, Lloyd T. Lam, Kenton L. Longenecker, Mai H. Bui, Kenneth B. Idler, Keith B. Glaser, Julie L. Wilsbacher, Chris Tse, William N. Pappano, Tzu-Hsuan Huang	27
3	Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemia 2012 ·Leukemia & lymphoma ·Eunice S. Wang, Karen Yee, Liang Piu Koh, Donna E. Hogge, Sari H. Enschede, Dawn M. Carlson, Matthew W. Dudley, Keith B. Glaser, Evelyn McKeegan, Daniel H. Albert, Xiaohui Li, Rajendra Pradhan, Wendy Stock	18
4	Thienopyridine ureas as dual inhibitors of the VEGF and Aurora kinase families 2012 ·Bioorganic & Medicinal Chemistry Letters ·Michael L. Curtin, Robin R. Frey, H. Robin Heyman, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Terrance J. Magoc, Paul Tapang, Daniel H. Albert, Donald J. Osterling, Amanda M. Olson, Jennifer J. Bouska, Zhiwen Guan, Lee C. Preusser, James S. Polakowski, Kent D. Stewart, Chris Tse, Steven K. Davidsen, Michael R. Michaelides	19
5	The Multitargeted Receptor Tyrosine Kinase Inhibitor Linifanib (ABT-869) Induces Apoptosis through an Akt and Glycogen Synthase Kinase 3β–Dependent Pathway 2011 ·Molecular Cancer Therapeutics ·Jenny E. Hernandez‐Davies, Joan P. Zape, Elliot M. Landaw, Xiaolin Tan, Ajia Presnell, Diana Griffith, Michael C. Heinrich, Keith B. Glaser, Kathleen M. Sakamoto	24
6	Cyanobacterial Microcystis aeruginosa Lipopolysaccharide Elicits Release of Superoxide Anion, Thromboxane B2, Cytokines, Chemokines, and Matrix Metalloproteinase-9 by Rat Microglia 2011 ·Toxicological Sciences ·Alejandro M. S. Mayer, (unknown), (unknown), (unknown), (unknown), Mary L. Hall, Keith B. Glaser, John P. Berry	39
7	Identification of genes that confer tumor cell resistance to the Aurora B kinase inhibitor, AZD1152 2009 ·The Pharmacogenomics Journal ·Jun Guo, (unknown), Paul Tapang, Joann P. Palma, Luis E. Rodrı́guez, (unknown), (unknown), Jennifer J. Bouska, (unknown), Dimitri Semizarov, Daniel H. Albert, Cherrie K. Donawho, Keith B. Glaser, O. Jameel Shah	27
8	ABT-869, a multi-targeted tyrosine kinase inhibitor, in combination with rapamycin is effective for subcutaneous hepatocellular carcinoma xenograft 2008 ·Journal of Hepatology ·Viraj J. Jasinghe, Zhigang Xie, Jianbiao Zhou, (unknown), Lai-Fong Poon, Senthilnathan Palaniyandi, Keith B. Glaser, Daniel H. Albert, Steven K. Davidsen, Chien-Shing Chen	31
9	Identification of aminopyrazolopyridine ureas as potent VEGFR/PDGFR multitargeted kinase inhibitors 2007 ·Bioorganic & Medicinal Chemistry Letters ·Yujia Dai, (unknown), Niru B. Soni, Lori J. Pease, David R. Reuter, Amanda M. Olson, Donald J. Osterling, Stella Z. Doktor, Daniel H. Albert, Jennifer J. Bouska, Keith B. Glaser, Patrick A. Marcotte, Kent D. Stewart, Steven K. Davidsen, Michael R. Michaelides	31
10	HDAC inhibitors: Clinical update and mechanism-based potential 2007 ·Biochemical Pharmacology ·Keith B. Glaser	293
11	Thienopyridine urea inhibitors of KDR kinase 2006 ·Bioorganic & Medicinal Chemistry Letters ·H. Robin Heyman, Robin R. Frey, Peter F. Bousquet, George A. Cunha, Maria D. Moskey, Asma A. Ahmed, Niru B. Soni, Patrick A. Marcotte, Lori J. Pease, Keith B. Glaser, Melinda S. Yates, Jennifer J. Bouska, Daniel H. Albert, (unknown), Peter J. Dandliker, Kent D. Stewart, Paul Rafferty, Steven K. Davidsen, Michael R. Michaelides, Michael L. Curtin	33
12	ABT-869 a novel multi-targeted receptor tyrosine kinase inhibitor: characterization of FLT3 phosphorylation in a model of acute myelogenous leukemia 2005 ·Cancer Research ·Junling Li, Lori J. Pease, Paul Tapang, Jennifer McCall, (unknown), Daniel H. Albert, Yujia Dai, (unknown), Michael R. Michaelides, Steven K. Davidsen, Keith B. Glaser	0
13	Differential protein acetylation induced by novel histone deacetylase inhibitors 2004 ·Biochemical and Biophysical Research Communications ·Keith B. Glaser, (unknown), Lori J. Pease, Michael J. Staver, Patrick A. Marcotte, Jun Guo, Robin R. Frey, Robert B. Garland, H. Robin Heyman, Carol K. Wada, Anil Vasudevan, (unknown), Steven K. Davidsen, Michael L. Curtin	51
14	Expression and functional characterization of recombinant human HDAC1 and HDAC3 2004 ·Life Sciences ·Junling Li, Michael J. Staver, Michael L. Curtin, James H. Holms, Robin R. Frey, Rohinton Edalji, Richard A. Smith, (unknown), Steven K. Davidsen, Keith B. Glaser	37
15	Gene expression profiling of multiple histone deacetylase (HDAC) inhibitors: defining a common gene set produced by HDAC inhibition in T24 and MDA carcinoma cell lines. 2003 ·PubMed ·Keith B. Glaser, Michael J. Staver, Jeffrey F. Waring, Joshua D. Stender, Roger G. Ulrich, Steven K. Davidsen	445
16	Discovery of selective hydroxamic acid inhibitors of tumor necrosis factor-α converting enzyme 2001 ·Bioorganic & Medicinal Chemistry Letters ·James H. Holms, (unknown), Patrick A. Marcotte, (unknown), Junling Li, Lori J. Pease, Keith B. Glaser, Douglas W. Morgan, Michael R. Michaelides, Steven K. Davidsen	41
17	Enhancement of the surface expression of tumor necrosis factor α (TNFα) but not the p55 TNFα receptor in the THP-1 monocytic cell line by matrix metalloprotease inhibitors 1999 ·Biochemical Pharmacology ·Keith B. Glaser, Lori J. Pease, Junling Li, Douglas W. Morgan	20
18	Expression, release, and regulation of human TNFα from stable transfectants of HEK-293 cells 1997 ·Inflammation Research ·Keith B. Glaser, (unknown), Robert P. Metzger, Thoru Pederson, Lori J. Pease, Kazumi Shiosaki, Douglas W. Morgan	3
19	Cellular and Topical in vivo Inflammatory Murine Models in the Evaluation of Inhibitors of Phospholipase A<sub>2</sub> 1995 ·Skin Pharmacology and Physiology ·Keith B. Glaser, Mei-Li Amy Sung, David A. Hartman, (unknown), Jean Bauer, Thomas S. Walter, (unknown)	15
20	Pharmacological characterization of WAY-121,520: A potent anti-inflammatory indomethacin-based inhibitor of 5-lipoxygenase (5-LO)/phospholipase A2 (PLA2) 1993 ·Inflammation Research ·Keith B. Glaser, Richard P. Carlson, Anita Sung, Jean Bauer, (unknown), (unknown), (unknown), D S Hartman, Thomas S. Walter, (unknown), Ralph E. Howell, (unknown), D S Grimes, Dennis Kubrak, (unknown), Anthony F. Kreft, Barry M. Weichman	6

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact